Metraipolis › archive › dc_da9857377fe7

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours:… — Europe PMC PMID:42604001

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42604001
DOI
10.1016/j.eclinm.2026.104109
License (as archived)
solo-consultazione
Archived
2026-10-16T23:22:37.270Z
SHA-256 of the archived text
0359f3c8cd5dcff1a2a4648ac667f9027d598d3f93d1042480c5bcf862ee906b
Stable URL of this page
https://metraipolis.com/documento/dc_da9857377fe7

How to cite

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours:… — Europe PMC PMID:42604001 — Europe PMC (en), https://europepmc.org/article/MED/42604001 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da9857377fe7 (Metraipolis archive dc_da9857377fe7, sha256 0359f3c8cd5dcff1a2a4648ac667f9027d598d3f93d1042480c5bcf862ee906b)
BibTeX
@misc{dcda9857377fe7,
  title = {[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours:… — Europe PMC PMID:42604001},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42604001},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da9857377fe7; sha256 0359f3c8cd5dcff1a2a4648ac667f9027d598d3f93d1042480c5bcf862ee906b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42604001. Agents can read the archived copy with the MCP tool read_document.